The POTENTIAL OF CAESALPINIA CRISTA LEAVES IN THE TREATMENT OF ULCERATIVE COLITIS IN LABORATORY ANIMALS

  • Bharati Zaware Department of Pharmacy, Suresh Gyan Vihar University, Jaipur-302017, Rajasthan, India.
  • Ritu Gilhotra Department of Pharmacy, Suresh Gyan Vihar University, Jaipur-302017, Rajasthan, India.
  • Sanjay Chaudhari Rasiklal M. Dhariwal Institute of Pharmaceutical Education and Research, Chinchwad, Pune 411019, Maharashtra, India.

Abstract

The aim of present investigation was to study the Ulcerative colitis effect of extracts of Caesalpinia crista in acetic acid induced experimental colitis in Sprague Dawley rats. Sprague Dawley rats were divided into nine groups (n=6). The rats were received 7 days pretreatment with chloroform, ethyl acetate, ethanolic extracts of C. crista 200 mg/kg and 400 mg/kg. Ulcerative colitis was induced by intrarectal administration of 1ml of 4% acetic acid solution on 8th day. Prednisolone (2 mg/kg) was used as standard drug administered orally for 3 days. After 48 hrs of colitis induction animals were sacrificed by cervical dislocation to remove colon and distal 5 cm of the colon was dissected. Macroscopical study, Ulcer index of the colon, colonic myeloperoxidase (MPO) and malondialdehyde (MDA) level in colon tissue and blood were studied. Intrarectal instillation of acetic acid caused enhanced ulcer index, myeloperoxidase and malondialdehyde. Ethanol extract of C.crista showed significant effect in lowering ulcer index as well as neutrophil infiltration at a dose of 400 mg/kg in acetic acid induced colitis. The present investigation demonstrates that the ethanol extract of C.crista is of potent therapeutic value in the amelioration of experimental colitis in rat by inhibiting the inflammatory mediator.

Downloads

Download data is not yet available.

Author Biographies

Bharati Zaware, Department of Pharmacy, Suresh Gyan Vihar University, Jaipur-302017, Rajasthan, India.

Department of Pharmacy, Suresh Gyan Vihar University, Jaipur-302017, Rajasthan, India.

Ritu Gilhotra, Department of Pharmacy, Suresh Gyan Vihar University, Jaipur-302017, Rajasthan, India.

Department of Pharmacy, Suresh Gyan Vihar University, Jaipur-302017, Rajasthan, India.

Sanjay Chaudhari, Rasiklal M. Dhariwal Institute of Pharmaceutical Education and Research, Chinchwad, Pune 411019, Maharashtra, India.

Rasiklal M. Dhariwal Institute of Pharmaceutical Education and Research, Chinchwad, Pune 411019, Maharashtra, India.

References

1. Jagtap AG, Shirke SS, Phadke AS, Effect of polyherbal formulation on experimental models of inflammatory bowel diseases, J Ethnopharmacol, 2004; 90(2-3):195–204.
2. Papadakis KA, Targan SR, Role of cytokines in the pathogenesis of inflammatory bowel disease, Annu Rev Med, 2000; 51:289–98.
3. Fiocchi C, Inflammatory bowel disease: Etiology and pathogenesis, Gastroenterology, 1998; 115:182-205.
4. Papadakis KA, Targan SR, Current theories on the cause of inflammatory bowel disease, Gastroenterol Clin North Am, 1999; 28:283-96.
5. Rutgeerts P, Geboes K, Understanding inflammatory bowel disease–the clinician’s perspective, Eur J Surg Suppl, 2001; 586:66-72.
6. Hyam SR, Jang SE, Jeong JJ, Joh EH, Han MJ, Kim DH, Echinocystic acid, a metabolite of lancemaside A, inhibits TNBS-induced colitis in mice, International Immunopharmacology, 2013; 15:433-41.
7. Pullman WE, Elsbury S, Kobayashi M, Hapel AJ, Doe WF, Enhanced mucosal cytokineproduction in inflammatory bowel disease, Gastroenterology, 1992; 102:529-37.
8. Mohsen M, Alireza G, Parvin M, Elham JS, Comparative study of Beeberis vulgaris fruit extract and Berberin chloride effect on acetic acid induced colitis in rats, Iranian Journal of Pharmaceutical Research, 2011; 10: 97-104.
9. Ashry EE, Abdellatief RB, Mohamed AE, Kotb HI, Protective effect of Ketamine against acetic acid induced ulcerative colitis in rats, Pharmacology and Pharmacy, 2016; 7:9-18.
10. Strober W, Fuss IJ, Blumberg RS, The immunology of mucosal models of inflammation, Annual Review Immunology, 2002; 20: 495-549.
11. Fabia R, Willen R, Rajab AA, Andersson R, Ahren B, Bengmark S, Acetic acid-induced colitis in the rat: Areproducible experimental model for acute ulcerative colitis, Eur. Surg. Res, 1992; 24:211-25.
12. Mashtoub S, Hoang BV, Vu M, Lymn KA, Feinle-Bisset C, Howarth GS, Clinical and structural effects of traditional Chinese medicine and the herbal preparation, Iberogast, in a rat model of ulcerative colitis, J Evid Based Complementary Altern Med, 2014; 19(1):10–9.
13. Rahimi R, Mozaffari S, Abdollahi M, On the use of herbal medicines in management of inflammatory bowel diseases: a systematic review of animal and human studies, Digestive Diseases and Science, 2009; 54:471-80.
14. Fei Ke, Yadav PK, Liuzhan Ju, Herbal medicine in the treatment of Ulcerative colitis, The Saudi Journal of Gastroenterology, 2012; 18 (1):3-10.
15. S. K. Kalauni, S. Awale, Y. Tezuka, A. H. Banskota, T. Z. Linn, and S. Kadota, “Methyl migrated cassane-type furanoditerpenes of Caesalpinia crista from Myanmar,” Chemical and Pharmaceutical Bulletin, 2005; 53(10):1300–1304.
16. Williamson EM. Major Herbs of Ayurveda, Elsevier Health Sciences, Edinburgh. UK: 2002.
17. Kirtikar KR, Basu BD. Indian medicinal plants. Vol 2, 2nd ed. Dehradun, India: Bishen Singh Mahendra Pal Singh; 1975. P. 842–844.
18. Neogi NC, Nayak KP. Biological investigation of Caesalpinia bonducella F. Indian J Pharmacol 1958; 20:95–100.
19. Adesina SK, Studies on some plants used as anticonvulsant in Amerindian and African traditional medicine, Fitoterapia, 1982; 53:147–162.
20. Dhar ML, Dhar MM, Dhawan BN, Mehrotra BN, Roy C, Screening of Indian plants for biological activity, Indian J Exp Biol, 1968;6:232–247.
21. Khandelwal KR. Practical Pharmacognosy Techniques and Experiments. 8th ed. Pune: Nirali Prakashan; 2007. P 149-53.
22. Kokate CK. Practical Pharmacognosy. New Delhi: Vallabh Prakashan; 2005. P 107-08, 115-20, 122-23.
23. Preeja G, Pillaia , Suresh P, European J Scientific Research, 2011; 53:462-469
24. Millar AD, Rampton DS, Chander CL, Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis, Gut, 1996; 39(3):407-15.
25. Mascolo N, Izzo A, Autore G, Maiello F, Carlo G, Capasso F, Acetic acid- induced colitis in normal and essential fatty acid deficient rats, J Pharmacol Exp Ther, 1995; 272:469-75.
26. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL, Hapten-induced model of chronic inflammation and ulceration in the rat colon, Gastroenterology, 1989; 96:795-803.
27. Zaware BB, Nirmal SA, Baheti DG, Patil AN, Mandal SC, Potential of Vitex negundo roots in the treatment of ulcerative colitis in mice, Pharmaceutical Biology, 2011; 49(8):1-5.
28. Murat Z, Mustafa K, Erhan A, Ozgur F, Murat A, Gokhan I, The comparative effects of calcium channel blockers in an experimental colitis model in rats, Turk J Gastroenterol, 2004; 15:243-49.
29. Dighe SB, Kuchekar BS, Wankhede SB, Potential Of Oxalis Corniculata Linn in the treatment of Ulcerative colitis, International Journal of Pharma and Bio Science, 2015; 6(3):117-25.
30. Evans M, Laszlo R, Brendan J, Whitlle R, Site specific lesion formation inflammation and inducible nitric oxide synthase expression by indomethacin in the rat intestine, European Journal Pharmacology, 2000; 388:281-85.
31. Ganjare AB, Nirmal SA, Patil AN, Use of apigenin from Cordia dichotoma in the treatment of colitis, Fitoterapia, 2011; 82:1052-56.
32. Jagtap AG, Shirke SS, Phadke AS, Effect of polyherbal formulation on experimental models of inflammatory bowel disease, Journal of Ethnopharmacology, 2004; 90:195-204
33. Nakhai LA, Mohammadirad A, Yasa N, Minaie B, Nikfar S, Ghazanfari G, Benefits of Zataria multiflora Boiss in experimental model of mouse inflammatory bowel disease, Evidence- Based Complementary Alternative Medicine, 2007; 4:43-50.
34. Macpherson B, Pfeiffer C, Experimental production of diffuse colitis in rats, Digestion, 1978; 17:135-50.
35. Ardizzone S, Bianchi PG, Biologic therapy for inflammatory bowel disease. Drugs, 2005; 65:2253-86.
36. Nakamura K, Honda K, Mizutani T, Akiho H, Harada N, Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules, World Journal of Gastroenterology, 2006; 12(29):4628-35.
37. Krawisz JE, Sharon P, Stenson WE, Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity, Assessment of inflammation in rat and hamster models, Gastroenterology, 1984; 87:1344-50.
38. Joshi SV, Vyas BA, Shah PD, Shah DR, Shah SA, Gandhi TR, Protective effect of aqueous extract of Oroxylum indicum Linn. (root bark) against DNBS-induced colitis in rats, Indian Journal of Pharmacology, 2011; 43(6):656-61.
39. Shiratora Y, Aoki S, Takada H, Kiriyama H, Ohto K, Hai K, Oxygen-derived free radical generating capacity of polymorphonuclear cells in patients with ulcerative colitis, Digestion, 1989; 44:163-71.
40. Zama D, Meraihi Z, Tebibel S, Benayssa W, Benayache F, Benayache S, Chlorpyrifos-induced oxidative stress and tissue damage in the liver, kidney, brain and fetus in pregnant rats: The protective role of the butanolic extract of Paronychia argentea L, Indian Journal of Pharmacology, 2007; 39(3):145-50.
41. Ohkawa H, Ohishi N, Yagi K, Assay for lipid peroxidase in animal tissues by thiobarbituric acid reaction, Analytical Biochemistry, 1979; 95:351-58.
42. Sharma V, Rajani GP, Evaluation of Caesalpinia pulcherrima Linn. for anti-inflammatory and antiulcer activities, Indian Journal of Pharmacology, 2011; 43(2):168-71.
Statistics
32 Views | 64 Downloads
How to Cite
Zaware, B., Gilhotra, R., & Chaudhari, S. (2018). The POTENTIAL OF CAESALPINIA CRISTA LEAVES IN THE TREATMENT OF ULCERATIVE COLITIS IN LABORATORY ANIMALS. Journal of Drug Delivery and Therapeutics, 8(5), 374-381. https://doi.org/10.22270/jddt.v8i5.1933